OncoZenge participates in MASCC cancer care conference June 27-29
Stockholm, Sweden – June 4 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment for oral pain, today announces its participation in the 2024 Multinational Association of Supportive Care in Cancer (MASCC) annual meeting taking place in Lille, France on June 27-29, 2024.The MASCC annual meeting is a premier gathering of healthcare professionals dedicated to improving the quality of life for cancer patients. Consistent with MASCC’s purpose the conference focuses on the latest advancements and best practices in cancer supportive